Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today's Pharmaceutical Executive Daily, Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials, a dealmaking roundup covers Alteogen's up-to-$3.223-billion license deal with Novartis, NewBiologix's gene therapy manufacturing partnership with Synastra, and RedHill's acquisition of Rebyota and Clenpiq from Ferring, and Lexi Cogswell and Tom Rotolo argue that obesity medical strategy needs real-world insights, not just real-world evidence.

Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials this week after new safety concerns emerge. Novartis halts a total of eight autoimmune studies of Rap-cel, spanning lupus, myasthenia gravis, and multiple sclerosis, following three fatal cases of immune effector cell-associated hemophagocytic syndrome, though its cancer studies with the therapy continue unaffected. Separately, Bristol Myers Squibb halts enrollment in its Zola-cel autoimmune trials, including a planned systemic sclerosis study, after routine monitoring detects transient, reversible inflammatory events; the company says it is reviewing the data out of an abundance of caution and aims to resume as quickly as possible.

A trio of dealmaking headlines round out the week. Alteogen enters an option and license agreement with Novartis worth up to $3.223 billion, giving Novartis rights to develop subcutaneous formulations of its biologics using Alteogen's ALT-B4 hyaluronidase, a technology that converts IV drugs into faster-acting under-the-skin versions. Separately, NewBiologix partners with Synastra Biotechnology to develop a stable producer cell line for Synastra's investigational Duchenne muscular dystrophy gene therapy, aiming to solve manufacturing bottlenecks for high-dose viral vector treatments. And RedHill Biopharma acquires exclusive global rights to Ferring Pharmaceuticals' Rebyota, a microbiota-based therapy for preventing C. difficile recurrence, and U.S. rights to Clenpiq, a bowel-prep product, for $12 million upfront plus royalties and milestones.

Finally, Lexi Cogswell and Tom Rotolo argue that pharmaceutical medical strategy in obesity care needs to shift from simply reporting real-world evidence to generating real-world insights that explain why outcomes happen and what to do next. The authors contend that traditional data dissemination is no longer enough as obesity rates climb, and that companies need frameworks built to understand patient journeys, support healthcare professionals, and demonstrate the value of innovation in actual clinical settings. They frame the moment as one of the most significant evolutions in medical strategy in decades.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.